Bath Savings Trust Co Has $1,669,000 Stake in Eli Lilly and Company (LLY)

Bath Savings Trust Co held its stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,272 shares of the company’s stock at the close of the 2nd quarter. Bath Savings Trust Co’s holdings in Eli Lilly and were worth $1,669,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. BlackRock Inc. increased its stake in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. State Street Corp increased its stake in Eli Lilly and by 1.6% in the 1st quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Geode Capital Management LLC increased its stake in Eli Lilly and by 8.4% in the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC increased its stake in Eli Lilly and by 2.8% in the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares during the last quarter. Hedge funds and other institutional investors own 75.77% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 825,000 shares of company stock worth $68,456,650. 0.20% of the stock is owned by insiders.

A number of research analysts have recently commented on LLY shares. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a research report on Tuesday, May 16th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective for the company. in a research report on Wednesday, July 26th. Finally, TheStreet downgraded shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $88.07.

Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.38% during trading on Tuesday, reaching $82.32. 1,043,737 shares of the company’s stock traded hands. The company has a market cap of $86.85 billion, a price-to-earnings ratio of 35.62 and a beta of 0.34. The company’s 50-day moving average is $80.88 and its 200 day moving average is $82.05. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the firm earned $0.86 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/09/12/bath-savings-trust-co-has-1669000-stake-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply